Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by wildbird1on Sep 30, 2018 1:02pm
153 Views
Post# 28717358

Test volume...

Test volume...PressRelease Aug 15, 2018...
Genenews said (Quote) Test volume has grow 40% in July over previous months (End of Quote).

Question? 
In the next financial, should we anticipate in August & September 2018 a bigger increase than the 40% increase in July 2018?

Answer; Probably a big yes...

Why?
Because according to the PressRelease Aug 15, 2018...In Aug 2018, Genenews new partner AIM Laboratories with it's very big distribution network (20 States and growing) has begun to sell genenews multiple cancer tests( in July 2018, AIM wasn't selling Genenews cancer tests).
The result of this is that in August & September 2018, thank's to AIM Laboratories big distribution network we should see a much bigger increase in tests volume than the 40% in July.

Conclusion ...
The next financial should be of crutial importance as we should see for the first time a very big increase in ''tests volume'' over the previous months.
Bullboard Posts